Eli Lilly has reported positive top-line results from two Phase 3 studies of its triple-hormone receptor agonist retatrutide, with the experimental obesity treatment meeting the primary endpoints in both trials. However, the drug produced lower peak weight loss than seen in some earlier studies involving different patient populations and did not demonstrate a significant reduction in cardiovascular events.
The company evaluated multiple doses of retatrutide, which targets the GIP, GLP-1 and glucagon receptors, in two late-stage trials. TRIUMPH-2 enrolled 1,152 adults with obesity and Type 2 diabetes, while TRIUMPH-3 included 1,949 participants with serious obesity and verified cardiovascular disease.
Using the efficacy estimand, which analyzes outcomes among participants who remained on their assigned treatment without using forbidden weight-loss therapies, patients receiving the 12 mg dose in TRIUMPH-2 achieved an average weight reduction of just under 21% after 80 weeks. Participants in the placebo group recorded an average weight loss of 3.2%.
In TRIUMPH-3, the highest dose of retatrutide resulted in an average weight loss of 22.6% at 80 weeks, compared with just over 3% for placebo recipients, allowing the study to meet its primary efficacy objective.
Although successful, both trials produced lower weight-loss figures than earlier Phase 3 studies. TRIUMPH-4 reported a 28.7% average reduction in body weight after 68 weeks among patients with obesity and knee osteoarthritis, while TRIUMPH-1 demonstrated 28.3% weight loss over 80 weeks. Those studies, however, did not include patients with Type 2 diabetes, a population that typically experiences more modest weight-loss outcomes.
Following the TRIUMPH-1 results announced in May, analysts at Citi noted that placebo-adjusted weight loss had modestly exceeded Wall Street’s expectations of 25%, although they suggested some investors had anticipated even stronger efficacy.
Safety findings showed that treatment discontinuation due to adverse events occurred in 7.7% of participants receiving retatrutide in TRIUMPH-2, increasing to 11.6% among those treated with the 9 mg dose. In TRIUMPH-3, 13.5% of patients assigned to the 12 mg regimen discontinued therapy because of adverse events. That rate was smarginally higher than the 11.3% discontinuation rate reported previously in TRIUMPH-1, a result that had been viewed positively by analysts.
Consistent with other GLP-1-based therapies, gastrointestinal side effects were among the most commonly reported adverse events. At the 12 mg dose, diarrhea was reported in 33.6% of participants in TRIUMPH-2 and 24.4% in TRIUMPH-3. Nausea affected 38% and 22.4% of patients, respectively, while constipation occurred in 16.8% and 15.7% of the people.
TRIUMPH-3 also evaluated whether retatrutide could reduce major adverse cardiovascular events. Across both retatrutide treatment groups, 44 such events, including cardiovascular death, heart attack and coronary revascularization, were recorded, compared with 52 in the placebo arm. Lilly said the study did not demonstrate a clear cardiovascular benefit because the number of events in both treatment and placebo groups was substantially lower than originally anticipated.
The therapy did, however, improve several cardiovascular risk markers. Patients receiving the 12 mg dose experienced average reductions of 37% in triglycerides, 16.5% in non-HDL cholesterol and just over 51% in high-sensitivity C-reactive protein.
Eli Lilly has reported encouraging clinical data for its investigational Triple G therapy, demonstrating significant weight loss in patients while leaving some uncertainty regarding its long-term cardiovascular risk reduction. The results reinforce Eli Lilly’s commitment to advancing next-generation obesity treatments that address both metabolic health and chronic disease management. Although the therapy achieved promising weight reduction outcomes, additional research will be needed to better understand its cardiovascular benefits.
Strong Weight Loss Performance
Clinical findings indicate that Eli Lilly’s Triple G drug produced meaningful weight loss across the study population. Participants experienced substantial reductions in body weight, highlighting the therapy’s potential as a new option for individuals living with obesity and related metabolic conditions.
Obesity is a chronic condition requiring long-term management. Eli Lilly is evaluating the durability of weight loss, patient adherence, and overall safety to determine how the therapy could fit into future treatment strategies for individuals with obesity.
Why Cardiovascular Benefits Require More Research
Additional late-stage clinical trials and long-term follow-up studies will provide greater clarity regarding the drug’s safety profile and cardiovascular outcomes. Eli Lilly is expected to continue expanding its research to support future regulatory submissions and potential commercialization.
Conclusion
The latest data demonstrate that Eli Lilly’s Triple G drug has the potential to become an important advancement in obesity treatment by delivering significant weight loss. While questions remain regarding its cardiovascular risk reduction benefits, ongoing research will help determine the therapy’s broader clinical value. As Eli Lilly continues to innovate in metabolic medicine, the results highlight the growing promise of next-generation obesity therapies.
